{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055673","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.986584+00:00","generated_at":"2026-06-02T12:08:20.149922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024","bullets":["Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).","Cash, equivalents & securities $311.1M (Dec 2023: $205.2M); boosted by $189.8M gross equity offering in Feb 2024.","Non-GAAP operating cash burn $58.7M in Q1 vs $74.8M YoY; full-year 2024 cash burn guided below $200M.","Four ongoing clinical programs (SC291, SC262, UP421) across seven indications; initial data expected throughout 2024.","R&D expenses $56.4M, down 16% from $67.2M, reflecting 2023 strategic repositioning and headcount reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055673","json":"https://secwatch.observer/filing/0000950170-24-055673.json","markdown":"https://secwatch.observer/filing/0000950170-24-055673.md","text":"https://secwatch.observer/filing/0000950170-24-055673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/0000950170-24-055673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/sana-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:08:20.149922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f99100dd30285bfb453df675c64e44de4cf1f1f","claim":"Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/0000950170-24-055673-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}